Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 791–800 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 791
- Medicine slug
- isradipine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
1.5 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf3425e0-428d-4bdb-ac9a-3b9d483df83a (opens source in a new tab)
Isradipine label
Version not recorded · Effective date not recorded
Isradipine is detectable in plasma within 20 minutes after administration of single oral doses of 2.5 to 20 mg, and peak concentrations of approximately 1 ng/mL/mg dosed occur about 1.5 hours after drug administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acf7c376-6cb6-4857-b455-0bf5da29346c (opens source in a new tab)
Isradipine label
Version not recorded · Effective date not recorded
Isradipine is detectable in plasma within 20 minutes after administration of single oral doses of 2.5 to 20 mg, and peak concentrations of approximately 1 ng/mL/mg dosed occur about 1.5 hours after drug administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdb4c50e-6e6f-a43d-e053-6294a90aa24f (opens source in a new tab)
Isradipine label
Version not recorded · Effective date not recorded
Isradipine is detectable in plasma within 20 minutes after administration of single oral doses of 2.5-20 mg, and peak concentrations of approximately 1 ng/mL/mg dosed occur about 1.5 hours after drug administration.
Projected row 792
- Medicine slug
- isradipine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
3 L/kg
- Numeric value
- 3
- Unit
- L/kg
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf3425e0-428d-4bdb-ac9a-3b9d483df83a (opens source in a new tab)
Isradipine label
Version not recorded · Effective date not recorded
The total body clearance of isradipine is 1.4 L/min and the apparent volume of distribution is 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acf7c376-6cb6-4857-b455-0bf5da29346c (opens source in a new tab)
Isradipine label
Version not recorded · Effective date not recorded
The total body clearance of isradipine is 1.4 L/min and the apparent volume of distribution is 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdb4c50e-6e6f-a43d-e053-6294a90aa24f (opens source in a new tab)
Isradipine label
Version not recorded · Effective date not recorded
The total body clearance of isradipine is 1.4 L/min and the apparent volume of distribution is 3 L/kg.
Projected row 793
- Medicine slug
- itraconazole
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
55%
- Numeric value
- 55
- Unit
- %
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6df5ff94-47ba-4881-abb4-b321e35a6955 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The observed absolute oral bioavailability of itraconazole is about 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68165d90-953c-e2f5-e053-2a91aa0ada25 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The observed absolute oral bioavailability of itraconazole is about 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46732a10-1f0d-4022-9689-256c44683e96 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The observed absolute oral bioavailability of itraconazole is about 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5af0b33d-bfa6-420b-86f0-067f95b402b2 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The observed absolute bioavailability of itraconazole under fed conditions is about 55% and increases by 30% when the oral solution is taken in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da63870d-b426-4e49-9591-5bb51f962e66 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The observed absolute bioavailability of itraconazole under fed conditions is about 55% and increases by 30% when the oral solution is taken in fasting conditions.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ab38a8a-3708-4b97-9f7f-8e554a15348d (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The observed absolute oral bioavailability of itraconazole is about 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1274d78-1096-4ae3-8299-a2e94eaa0ea5 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The observed absolute oral bioavailability of itraconazole is about 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9d8b5a7-435f-40e6-8596-5f2376b92c74 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The observed absolute oral bioavailability of itraconazole is about 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e564067e-e469-4c51-9076-75f89f5c5cdf (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The observed absolute oral bioavailability of itraconazole is about 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6242b7ad-eaa0-a524-b6e0-ec33e63407db (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The observed absolute oral bioavailability of itraconazole is about 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:349ffcf4-b2cd-4c93-9411-13c39275b8f3 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The observed absolute oral bioavailability of itraconazole is about 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4d555fa-787c-40fb-bb7d-b0d4f7318fd0 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The observed absolute oral bioavailability of itraconazole is about 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23126370-8d6a-4027-bd8f-860e2776ba3a (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The observed absolute oral bioavailability of itraconazole is about 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43ded1aa-f825-40fe-aa9a-addd36a07f06 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The observed absolute bioavailability of itraconazole under fed conditions is about 55% and increases by 30% when the oral solution is taken in fasting conditions.
Projected row 794
- Medicine slug
- itraconazole
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 0.933333
- Recorded readings
16 to 28 hours
- Numeric value
- 16
- Unit
- hours
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6df5ff94-47ba-4881-abb4-b321e35a6955 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68165d90-953c-e2f5-e053-2a91aa0ada25 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46732a10-1f0d-4022-9689-256c44683e96 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5af0b33d-bfa6-420b-86f0-067f95b402b2 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da63870d-b426-4e49-9591-5bb51f962e66 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ab38a8a-3708-4b97-9f7f-8e554a15348d (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1274d78-1096-4ae3-8299-a2e94eaa0ea5 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9d8b5a7-435f-40e6-8596-5f2376b92c74 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e564067e-e469-4c51-9076-75f89f5c5cdf (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6242b7ad-eaa0-a524-b6e0-ec33e63407db (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:349ffcf4-b2cd-4c93-9411-13c39275b8f3 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4d555fa-787c-40fb-bb7d-b0d4f7318fd0 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23126370-8d6a-4027-bd8f-860e2776ba3a (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43ded1aa-f825-40fe-aa9a-addd36a07f06 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing.
37 ± 17 hours
- Numeric value
- 37
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:306352d1-9d5a-49ad-b72d-893b99546861 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
A statistically significant reduction in mean C max (47%) and a twofold increase in the elimination half-life (37 ± 17 hours vs. 16 ± 5 hours) of itraconazole were noted in cirrhotic subjects compared with healthy subjects.
Projected row 795
- Medicine slug
- itraconazole
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 0.733333
- Recorded readings
2 to 5 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6df5ff94-47ba-4881-abb4-b321e35a6955 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism: General Pharmacokinetic Characteristics Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68165d90-953c-e2f5-e053-2a91aa0ada25 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism: General Pharmacokinetic Characteristics Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46732a10-1f0d-4022-9689-256c44683e96 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism General Pharmacokinetic Characteristics Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ab38a8a-3708-4b97-9f7f-8e554a15348d (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism: General Pharmacokinetic Characteristics Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1274d78-1096-4ae3-8299-a2e94eaa0ea5 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism: General Pharmacokinetic Characteristics Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9d8b5a7-435f-40e6-8596-5f2376b92c74 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
CLINICAL PHARMACOLOGY General Pharmacokinetic Characteristics Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e564067e-e469-4c51-9076-75f89f5c5cdf (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism: General Pharmacokinetic Characteristics Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6242b7ad-eaa0-a524-b6e0-ec33e63407db (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism General Pharmacokinetic Characteristics Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:349ffcf4-b2cd-4c93-9411-13c39275b8f3 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism: General Pharmacokinetic Characteristics Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4d555fa-787c-40fb-bb7d-b0d4f7318fd0 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism General Pharmacokinetic Characteristics Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23126370-8d6a-4027-bd8f-860e2776ba3a (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism: General Pharmacokinetic Characteristics Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration.
2.5 hours
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5af0b33d-bfa6-420b-86f0-067f95b402b2 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism: Itraconazole General Pharmacokinetic Characteristics Peak plasma concentrations are reached within 2.5 hours following administration of the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da63870d-b426-4e49-9591-5bb51f962e66 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism: Itraconazole General Pharmacokinetic Characteristics Peak plasma concentrations are reached within 2.5 hours following administration of the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43ded1aa-f825-40fe-aa9a-addd36a07f06 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism: Itraconazole General Pharmacokinetic Characteristics Peak plasma concentrations are reached within 2.5 hours following administration of the oral solution.
2 to 6 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:306352d1-9d5a-49ad-b72d-893b99546861 (opens source in a new tab)
Itraconazole label
Version not recorded · Effective date not recorded
(hr*mcg/ml) 15.6 ± 3.7 14.9 ±3.8 C trough (mcg/ml) 1.2 ±0.4 1.0±0.3 C max,ss (mcg/ml) 1.6 ±0.4 1.5 ±0.4 T max,ss (h) 7.0 (1-10) 5.0 (1-8) Peak plasma concentrations of itraconazole after administration of a single dose of TOLSURA are reached within 2 to 6 hours following oral administration in either the fasted or fed states.
Projected row 796
- Medicine slug
- ivabradine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
40%
- Numeric value
- 40
- Unit
- %
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e70f883-8c01-4ac2-815d-4a6d561c711a (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53f15531-796d-442b-a73c-05f048218531 (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:236cc914-7eef-600c-e063-6394a90a4bd1 (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92018a65-38f6-45f7-91d4-a34921b81d0d (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51ac7345-3188-4382-ab1d-9120d6c88927 (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e881a1ac-9221-4682-939f-966679cfe286 (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ead1cf3-e61a-49c4-e063-6294a90a330f (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:602d1c55-0e4d-452a-a087-888fdbaa7568 (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:676907d3-b374-4baa-8422-c04706409540 (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89134202-971b-4413-a9c9-d31a5c29722b (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5157767b-16d5-4a69-b6bd-95d360d19fda (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver.
Projected row 797
- Medicine slug
- ivabradine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
100 L
- Numeric value
- 100
- Unit
- L
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e70f883-8c01-4ac2-815d-4a6d561c711a (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
Ivabradine is approximately 70% plasma protein bound, and the volume of distribution at steady state is approximately 100 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53f15531-796d-442b-a73c-05f048218531 (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
Ivabradine is approximately 70% plasma protein bound, and the volume of distribution at steady state is approximately 100 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:236cc914-7eef-600c-e063-6394a90a4bd1 (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
Ivabradine is approximately 70% plasma protein bound, and the volume of distribution at steady state is approximately 100 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92018a65-38f6-45f7-91d4-a34921b81d0d (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
Ivabradine is approximately 70% plasma protein bound, and the volume of distribution at steady state is approximately 100 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51ac7345-3188-4382-ab1d-9120d6c88927 (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
Ivabradine is approximately 70% plasma protein bound, and the volume of distribution at steady state is approximately 100 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e881a1ac-9221-4682-939f-966679cfe286 (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
Ivabradine is approximately 70% plasma protein bound, and the volume of distribution at steady state is approximately 100 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ead1cf3-e61a-49c4-e063-6294a90a330f (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
Ivabradine is approximately 70% plasma protein bound, and the volume of distribution at steady state is approximately 100 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:602d1c55-0e4d-452a-a087-888fdbaa7568 (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
Ivabradine is approximately 70% plasma protein bound, and the volume of distribution at steady state is approximately 100 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:676907d3-b374-4baa-8422-c04706409540 (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
Ivabradine is approximately 70% plasma protein bound, and the volume of distribution at steady state is approximately 100 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89134202-971b-4413-a9c9-d31a5c29722b (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
Ivabradine is approximately 70% plasma protein bound and the volume of distribution at steady state is approximately 100 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5157767b-16d5-4a69-b6bd-95d360d19fda (opens source in a new tab)
Ivabradine label
Version not recorded · Effective date not recorded
Ivabradine is approximately 70% plasma protein bound, and the volume of distribution at steady state is approximately 100 L.
Projected row 798
- Medicine slug
- ivermectin
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 34
- Source count
- 18
- Agreement rate
- 0.555556
- Recorded readings
18 hours
- Numeric value
- 18
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:014e33e7-c07d-4feb-a2cf-7cd160b1facd (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
The plasma half-life of ivermectin in man is approximately 18 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:104a5045-94b1-4022-bc49-719521f30f0d (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
The plasma half-life of ivermectin in man is approximately 18 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cb062d7-0597-4e92-b2f6-7129a95e9500 (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
The plasma half-life of ivermectin in man is approximately 18 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e88adfbc-e375-4fea-827e-6ec51ed6fd0a (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
The plasma half-life of ivermectin in man is approximately 18 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad6539f2-94de-1bc5-e053-2a95a90a4cf2 (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
The plasma half-life of ivermectin in man is approximately 18 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:681888c9-af79-4b7d-ae80-c3f4f6f1effd (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
The plasma half-life of ivermectin in man is approximately 18 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:847a1dd7-d65b-4a0e-a67d-d90392059dac (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
The plasma half-life of ivermectin in man is approximately 18 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2de5ee45-0465-4996-ac00-5bdd352b4ed7 (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
The plasma half-life of ivermectin in man is approximately 18 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8005642-3bf0-41b9-8a53-8b933c68c073 (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
The plasma half-life of ivermectin in man is approximately 18 hours following oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fb17bc2-9192-4a0b-a3ee-fda9db035daa (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
The plasma half-life of ivermectin in man is approximately 18 hours following oral administration.
6.5 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1d5b166-ab06-4ab5-b0c6-31126238118a (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
Excretion The apparent terminal half-life averaged 6.5 days (mean ± standard deviation: 155± 40 hours, range 92-238 hours) in patients receiving a once daily cutaneous application of SOOLANTRA cream for 28 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of SOOLANTRA cream in treating rosacea lesions is unknown. 12.2 Pharmacodynamics Cardiac Electrophysiology At ther
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b4a7400-d34c-4947-90e6-340f7087a702 (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
Excretion The apparent terminal half-life averaged 6.5 days (mean ± standard deviation: 155 hours ± 40 hours, range 92 hours to 238 hours) in patients receiving a once daily cutaneous application of ivermectin cream for 28 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of ivermectin cream in treating rosacea lesions is unknown. 12.2 Pharmacodynamics Cardiac Electro
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81193a2d-dc0a-4ce5-a5c1-6dfd3195c4bc (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
Excretion The apparent terminal half-life averaged 6.5 days (mean ± standard deviation: 155± 40 hours, range 92 to 238 hours) in patients receiving a once daily cutaneous application of ivermectin cream for 28 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of ivermectin cream in treating rosacea lesions is unknown. 12.2 Pharmacodynamics Cardiac Electrophysiology At
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75973e89-a03f-48dd-8fe8-8eafc1938d09 (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
Excretion The apparent terminal half-life averaged 6.5 days (mean ± standard deviation: 155 ± 40 hours, range 92-238 hours) in patients receiving a once daily cutaneous application of ivermectin cream for 28 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of ivermectin cream in treating rosacea lesions is unknown. 12.2 Pharmacodynamics Cardiac Electrophysiology At t
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39fbf2b3-cd2f-4e04-99c4-ca4390fae2bd (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
Excretion The apparent terminal half-life averaged 6.5 days (mean ± standard deviation: 155± 40 hours, range 92-238 hours) in patients receiving a once daily cutaneous application of Ivermectin cream for 28 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of Ivermectin cream in treating rosacea lesions is unknown. 12.2 Pharmacodynamics Cardiac Electrophysiology At th
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d3e7aea-02a4-46b1-8a14-0324e4777cb4 (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
Excretion The apparent terminal half-life averaged 6.5 days (mean ± standard deviation: 155 ± 40 hours, range 92-238 hours) in patients receiving a once daily cutaneous application of ivermectin cream for 28 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of ivermectin cream in treating rosacea lesions is unknown. 12.2 Pharmacodynamics Cardiac Electrophysiology At t
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1061e454-d1dc-4293-b18d-9c8717fbbb40 (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
Excretion The apparent terminal half-life averaged 6.5 days (mean ± standard deviation: 155 ± 40 hours, range 92-238 hours) in patients receiving a once daily cutaneous application of ivermectin cream for 28 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of ivermectin cream in treating rosacea lesions is unknown. 12.2 Pharmacodynamics Cardiac Electrophysiology At t
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de9253c3-7d66-47fe-8ad7-8c0d4ee8ebda (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
Excretion The apparent terminal half-life averaged 6.5 days (mean ± standard deviation: 155± 40 hours, range 92 to 238 hours) in patients receiving a once daily cutaneous application of ivermectin cream for 28 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of ivermectin cream in treating rosacea lesions is unknown. 12.2 Pharmacodynamics Cardiac Electrophysiology At
Projected row 799
- Medicine slug
- ivermectin
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 34
- Source count
- 8
- Agreement rate
- 0.875
- Recorded readings
10 ± 8 hours
- Numeric value
- 10
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1d5b166-ab06-4ab5-b0c6-31126238118a (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
At steady state (after 2 weeks of treatment), the highest mean ± standard deviation plasma concentrations of ivermectin peaked (T max ) at 10 ± 8 hours post dose, the maximum concentration (C max ) was 2.10 ± 1.04 ng/mL (range: 0.69 - 4.02 ng/mL) and the area under the concentration curve (AUC 0-24hr ) was 36.14 ± 15.56 ng.hr/mL (range: 13.69-75.16 ng.hr/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81193a2d-dc0a-4ce5-a5c1-6dfd3195c4bc (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
At steady state (after 2 weeks of treatment), the highest mean ± standard deviation) plasma concentrations of ivermectin peaked (T max ) at 10 ± 8 hours post-dose, the maximum concentration (C max ) was 2.10 ± 1.04 ng/mL (range: 0.69 to 4.02 ng/mL) and the area under the concentration curve (AUC 0-24hr ) was 36.14 ± 15.56 ng.hr/mL (range: 13.69 to 75.16 ng•hr/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75973e89-a03f-48dd-8fe8-8eafc1938d09 (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
At steady state (after 2 weeks of treatment), the highest mean ± standard deviation plasma concentrations of ivermectin peaked (T max ) at 10 ± 8 hours post-dose, the maximum concentration (C max ) was 2.10 ± 1.04 ng/mL (range: 0.69 - 4.02 ng/mL) and the area under the concentration curve (AUC 0-24hr ) was 36.14 ± 15.56 ng.hr/mL (range: 13.69-75.16 ng.hr/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39fbf2b3-cd2f-4e04-99c4-ca4390fae2bd (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
At steady state (after 2 weeks of treatment), the highest mean ± standard deviation plasma concentrations of ivermectin peaked (T max ) at 10 ± 8 hours post dose, the maximum concentration (C max ) was 2.10 ± 1.04 ng/mL (range: 0.69 - 4.02 ng/mL) and the area under the concentration curve (AUC 0-24hr ) was 36.14 ± 15.56 ng.hr/mL (range: 13.69-75.16 ng.hr/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d3e7aea-02a4-46b1-8a14-0324e4777cb4 (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
At steady state (after 2 weeks of treatment), the highest mean ± standard deviation plasma concentrations of ivermectin peaked (T max ) at 10 ± 8 hours post-dose, the maximum concentration (C max ) was 2.10 ± 1.04 ng/mL (range: 0.69 - 4.02 ng/mL) and the area under the concentration curve (AUC 0-24hr ) was 36.14 ± 15.56 ng.hr/mL (range: 13.69-75.16 ng.hr/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1061e454-d1dc-4293-b18d-9c8717fbbb40 (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
At steady state (after 2 weeks of treatment), the highest mean ± standard deviation plasma concentrations of ivermectin peaked (T max ) at 10 ± 8 hours post-dose, the maximum concentration (C max ) was 2.10 ± 1.04 ng/mL (range: 0.69 - 4.02 ng/mL) and the area under the concentration curve (AUC 0-24hr ) was 36.14 ± 15.56 ng.hr/mL (range: 13.69-75.16 ng.hr/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de9253c3-7d66-47fe-8ad7-8c0d4ee8ebda (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
At steady state (after 2 weeks of treatment), the highest mean ± standard deviation) plasma concentrations of ivermectin peaked (T max ) at 10 ± 8 hours post-dose, the maximum concentration (C max ) was 2.10 ± 1.04 ng/mL (range: 0.69 to 4.02 ng/mL) and the area under the concentration curve (AUC 0-24hr ) was 36.14 ± 15.56 ng.hr/mL (range: 13.69 to 75.16 ng•hr/mL).
10 hours
- Numeric value
- 10
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b4a7400-d34c-4947-90e6-340f7087a702 (opens source in a new tab)
Ivermectin label
Version not recorded · Effective date not recorded
At steady state (after 2 weeks of treatment), the highest mean ± standard deviation) plasma concentrations of ivermectin peaked (T max ) at 10 hours ± 8 hours post-dose, the maximum concentration (C max ) was 2.10 ng/mL ± 1.04 ng/mL (range: 0.69 ng/mL to 4.02 ng/mL) and the area under the concentration curve (AUC 0-24hr ) was 36.14 ng.hr/mL ± 15.56 ng.hr/mL (range: 13.69 ng.hr/mL to 75.16 ng.hr/mL
Projected row 800
- Medicine slug
- ketoconazole
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 59
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
65%
- Numeric value
- 65
- Unit
- %
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d598696-c6f3-4b7c-ad73-949d2089df35 (opens source in a new tab)
Ketoconazole label
Version not recorded · Effective date not recorded
When ketoconazole was administered with non-diet cola after pretreatment with omeprazole, the bioavailability was 65% of that after administration of ketoconazole alone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ea8a22b-cd61-4623-a11f-43e3396b50fa (opens source in a new tab)
Ketoconazole label
Version not recorded · Effective date not recorded
When ketoconazole was administered with non-diet cola after pretreatment with omeprazole, the bioavailability was 65% of that after administration of ketoconazole alone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5dc1e67-639f-5476-e053-2995a90a4210 (opens source in a new tab)
Ketoconazole label
Version not recorded · Effective date not recorded
When ketoconazole was administered with non-diet cola after pretreatment with omeprazole, the bioavailability was 65% of that after administration of ketoconazole alone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f162e616-21b4-49b1-b437-15e21001a6f0 (opens source in a new tab)
Ketoconazole label
Version not recorded · Effective date not recorded
When ketoconazole was administered with non-diet cola after pretreatment with omeprazole, the bioavailability was 65% of that after administration of ketoconazole alone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:369f31da-d3c3-49b8-956f-f70598760164 (opens source in a new tab)
Ketoconazole label
Version not recorded · Effective date not recorded
When ketoconazole was administered with non-diet cola after pretreatment with omeprazole, the bioavailability was 65% of that after administration of ketoconazole alone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ca815a8-bccb-4ee2-a042-922373329cae (opens source in a new tab)
Ketoconazole label
Version not recorded · Effective date not recorded
When ketoconazole was administered with non-diet cola after pretreatment with omeprazole, the bioavailability was 65% of that after administration of ketoconazole alone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:517c29fc-2a2a-4bd5-a8bb-b464a65d2be0 (opens source in a new tab)
Ketoconazole label
Version not recorded · Effective date not recorded
When ketoconazole was administered with non-diet cola after pretreatment with omeprazole, the bioavailability was 65% of that after administration of ketoconazole alone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d4be760-c723-4f54-a854-12c61cf91703 (opens source in a new tab)
Ketoconazole label
Version not recorded · Effective date not recorded
When ketoconazole was administered with non-diet cola after pretreatment with omeprazole, the bioavailability was 65% of that after administration of ketoconazole alone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57e81e13-b395-4dbd-b660-3038de41a838 (opens source in a new tab)
Ketoconazole label
Version not recorded · Effective date not recorded
When ketoconazole was administered with non-diet cola after pretreatment with omeprazole, the bioavailability was 65% of that after administration of ketoconazole alone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc189ce2-3f10-260d-e053-2a95a90ae808 (opens source in a new tab)
Ketoconazole label
Version not recorded · Effective date not recorded
When ketoconazole was administered with non-diet cola after pretreatment with omeprazole, the bioavailability was 65% of that after administration of ketoconazole alone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9fc4618-4d87-47ef-ab3c-c9ffac3ba9b7 (opens source in a new tab)
Ketoconazole label
Version not recorded · Effective date not recorded
When ketoconazole was administered with non-diet cola after pretreatment with omeprazole, the bioavailability was 65% of that after administration of ketoconazole alone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4baebcab-a237-42c0-9183-6f447a44e371 (opens source in a new tab)
Ketoconazole label
Version not recorded · Effective date not recorded
When ketoconazole was administered with non-diet cola after pretreatment with omeprazole, the bioavailability was 65% of that after administration of ketoconazole alone.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=790Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.